The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 06, 2015
Filed:
Sep. 22, 2009
Applicant:
Kerry S. Campbell, Wyncote, PA (US);
Inventor:
Kerry S. Campbell, Wyncote, PA (US);
Assignee:
Fox Chase Cancer Center, Philadelphia, PA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); G01N 33/574 (2006.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 5/0783 (2010.01); G01N 33/50 (2006.01); C12N 5/02 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
C07K 14/70535 (2013.01); C07K 16/28 (2013.01); C07K 16/283 (2013.01); C07K 16/32 (2013.01); C12N 5/0646 (2013.01); G01N 33/5011 (2013.01); G01N 33/5047 (2013.01); A61K 2035/124 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/732 (2013.01); C12N 2501/23 (2013.01); C12N 2503/00 (2013.01); C12N 2503/02 (2013.01); C12N 2510/00 (2013.01);
Abstract
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.